



1

***Acute Aortic Syndromes:  
State of the Art***

**Kim A. Eagle, MD**



***Director***  
**Samuel & Jean Frankel Cardiovascular Center**  
**University of Michigan**

[keagle@umich.edu](mailto:keagle@umich.edu)  [@keaglemd](https://twitter.com/keaglemd)

2

## Disclosures: Kim A. Eagle

Registry

**IRAD**

International Registry  
of Aortic Dissection

Role: *Founder*

**GenTAC**

Genetically Triggered  
Aortic Conditions

Role: *Program Leader*

Research Grants


- Gore (Major Sponsor) • Terumo
- Mardigian Foundation • Varbedian Fund
- Hewlett Foundation • University of Michigan  
(Founding Sponsor)
- Medtronic
- Robert & Anne Aikens
- Marfan Foundation  
(GenTAC Alliance)

3

## Lecture Outline

- **Where have we been?**
  - Epidemiology
  - Classification
  - Clinical Presentation/ECG/Chest X-Ray
  - Static Imaging
  - Treatments
    - Medical
    - Non-Medical
- **Where are we headed?**
  - Genetics
  - Biomarkers
  - Dynamic Imaging
  - Survivorship
- **Reflections**

4



5

### Epidemiology: Aortic Dissection Community Study

- 52 incident dissections (6/100,000/yr)
- Risk factors
  - HTN – 67%
  - Smoking – 62%
  - BP poorly controlled pre-AoD
- 33/52 died, 18 (>50%) at home
- Hospital survivors: 5yr. survival
  - Type A – 86%
  - Type B – 83%

*Circulation 2013;127:2031-37.*

6

### Familiar Faces Lost or Affected by Aortic Dissections

- John Ritter:** Beloved actor, died suddenly from an aortic dissection (2003)
- Flo Hyman:** U.S. Olympic volleyball player, died from an aortic dissection at 31 (1986)
- Grant Wahl:** Respected journalist, collapsed at the FIFA World Cup in Qatar; due to an aortic dissection (2022)
- Lucille Ball:** Comedian, actress, and producer; aortic dissection at 77, died shortly after from other aorta issues (1989)
- James Donaldson:** 14 seasons NBA player for Seattle Sonics and the Dallas Mavericks, aortic dissection survivor
- Richie Faulkner:** Judas Priest guitarist, survived an on-stage aortic dissection during a 2021 concert




7

The John Ritter Foundation for Aortic Health

7


## “Acute Aortic Syndromes”

- Classic Aortic Dissection
- Intramural Hematoma
- Penetrating Aortic Ulcer
- Discrete Aortic Dissection (DiD)



8

## Types of Acute Aortic Syndromes




9

## Historical Classification by Time From Symptom Onset - Outdated


### Acute AoD

- Presentation within 14 days of onset



### Stanford Type A

Involves the ascending aorta  
with or without  
descending aorta




### Stanford Type B


Confined to descending aorta

Treasure T, et al. *J Heart Valve Dis* 1996;5:623-29.


10




11



12



13



14


## Demographics and Past History

| Variable            | All       | Type A   | Type B   | p-value |
|---------------------|-----------|----------|----------|---------|
|                     | (n=12725) | (n=8610) | (n=4115) |         |
| Age (yrs)           | 61.9      | 61.3     | 63.0     | <0.0001 |
| Male                | 65.6%     | 65.7%    | 65.4%    | NS      |
| HTN                 | 79.9%     | 77.6%    | 84.4%    | <0.0001 |
| Marfan              | 3.9%      | 3.4%     | 4.9%     | 0.0002  |
| Prior Heart Surgery | 15.9%     | 13.5%    | 20.7%    | <0.0001 |
| Iatrogenic          | 2.4%      | 2.8%     | 1.7%     | 0.0002  |
| Family History      | 9.7%      | 8.9%     | 11.5%    | 0.0003  |

IRAD Investigators.

15

## How Common is Aortic Dissection in ED Patients with Thoracic Pain?



Von Kodolitsch et al. Arch Intern Med 2000;160:2977-2982.

16

*Pain attending the splitting of the aortic wall is usually excruciating and extensive, radiating from midthorax front or back through the chest, down the back, and even into the thighs or up into the neck. The pain in the thorax or back comes suddenly at its maximum and is often prostrating, inducing a state of shock or even death.*

- Paul Dudley White, 1944


17

| IRAD                |              |              |              |               |
|---------------------|--------------|--------------|--------------|---------------|
| Presenting Symptoms |              |              |              |               |
| Variable            | All          | Type A       | Type B       | p-value       |
| • <b>Pain</b>       | 94.8%        | 94.4%        | 95.7%        | 0.0036        |
| <b>Abrupt</b>       | <b>82.4%</b> | <b>81.4%</b> | <b>84.5%</b> | <b>0.0001</b> |
| Anterior            | 87.7%        | 91.4%        | 78.8%        | <0.0001       |
| Back                | 54.7%        | 45.7%        | 71.5%        | <0.0001       |
| Abdominal           | 32.2%        | 26.2%        | 43.9%        | <0.0001       |
| Sharp               | 45.5%        | 43.3%        | 55.9%        | <0.0001       |
| Tearing             | 27.4%        | 25.6%        | 30.9%        | 0.0001        |
| • <b>Syncope</b>    | 12.8%        | 17.0%        | 3.8%         | <0.0001       |
| (n=12725)           |              |              |              |               |
| IRAD Investigators. |              |              |              |               |

18

| IRAD<br>Physical Exam |       |        |        |                     |
|-----------------------|-------|--------|--------|---------------------|
| Variable              | All   | Type A | Type B | p-value             |
| High BP               | 40.9% | 29.9%  | 63.3%  | <0.0001             |
| Low BP                | 11.5% | 15.4%  | 3.6%   | <0.0001             |
| Shock/Tamponade       | 8.0%  | 11.3%  | 1.2%   | <0.0001             |
| Murmur AI             | 19.8% | 26.4%  | 7.1%   | <0.0001             |
| Pulse Deficit         | 31.3% | 35.0%  | 24.8%  | <0.0001             |
| Stroke                | 5.5%  | 7.6%   | 1.4%   | <0.0001             |
| (n=12725)             |       |        |        | IRAD Investigators. |

19




20

| IRAD<br>EKG & CXR         |       |        |        |                     |
|---------------------------|-------|--------|--------|---------------------|
| Variable                  | All   | Type A | Type B | p-value             |
| • <b>CXR</b>              |       |        |        |                     |
| Normal                    | 30.0% | 30.6%  | 29.0%  | NS                  |
| Wide Mediast.<br>or Aorta | 69.9% | 69.9%  | 69.9%  | NS                  |
| PL. Effusion              | 14.8% | 12.4%  | 18.4%  | <0.001              |
| • <b>EKG</b>              |       |        |        |                     |
| Normal                    | 37.1% | 36.4%  | 38.3%  | NS                  |
| NSST-T Δ's                | 46.6% | 45.4%  | 49.1%  | 0.014               |
| Ischemia                  | 14.3% | 16.9%  | 9.1%   | <0.001              |
| New MI                    | 8.1%  | 10.3%  | 3.7%   | <0.001              |
| (n=9110)                  |       |        |        | IRAD Investigators. |


21

| How Many U.S. Adults have<br>Enlarged Aortas? |             |
|-----------------------------------------------|-------------|
| 4.2 – 4.4cm                                   | 3.8 Million |
| 4.5 – 4.9cm                                   | 1.6 Million |
| ≥ 5.0cm                                       | 0.2 Million |
| - R. Devereux                                 |             |


22




23




24




25



26



27



28

# Type B Aortic Dissection Acuity

- Uncomplicated**

  - No rupture
  - No malperfusion
  - No high-risk features
- Complicated**


  - Rupture
  - Malperfusion
- High Risk**

  - Refractory pain
  - Refractory hypertension
  - Bloody pleural effusion
  - Aortic diameter >40mm
  - Radiographic only malperfusion
  - Readmission
  - Entry tear: lesser curve location
  - False lumen diameter >22mm

Lombardi JV, et al. J Vasc Surg 2020;71:723-47.


29

# INSTEAD XL – Trial: Kaplan-Meier Estimates of Aortic Progression and Adverse Events



Nienaber C, et al. Circ Cardiovasc Interv 2013;6:407-416.

30



31


## INSTEAD XL – Trial Results

|                                         | OMT<br>(n=68) | OMT + TEVAR<br>(n=72) |         |
|-----------------------------------------|---------------|-----------------------|---------|
| <b>5 year follow-up</b>                 |               |                       |         |
| Maximum aortic diameter                 | 56.4±6.8      | 44.5±11.5             | <0.0001 |
| <b>True lumen diameter at level A</b>   | 18.7±6.7      | 32.6±5.5              | <0.0001 |
| <b>False lumen diameter at level A</b>  | 37.1±9.1      | 10.4±13.2             | <0.0001 |
| True lumen diameter at level B          | 16.9±7.2      | 28.6±6.4              | <0.0001 |
| False lumen diameter at level B         | 31.2±11.9     | 13.4±13.1             | <0.0001 |
| <b>False lumen thrombosis at 5 year</b> |               |                       |         |
| <b>Complete, number (%)</b>             | 11/50 (22.0)  | 48/53 (90.6)          | <0.0001 |
| <b>Partial, number (%)</b>              | 6/50 (12.0)   | 5/53 (9.4)            | 0.76    |

Nienaber C, et al. *Circ Cardiovasc Interv* 2013;6:407-416.

32

**Comparison of Medical Therapy to  
Endovascular Treatment in Type B Dissection:  
Long Term Follow-Up**



Fattori R, et al. *J Am Coll Cardiol Intv* 2013;6:876-82.

33

**Randomized Trials of Stent-Graft  
Therapy for Acute Stable Type B  
Aortic Dissection**



| Name         | Country | Target Enrollment | Duration |
|--------------|---------|-------------------|----------|
| Improve – AD | USA     | 1,100             | 7 Years  |
| Sunday       | Denmark | 554               | 5 Years  |
| Earnest      | UK      | 470               | 5 Years  |

Ref.

34

## False Lumen Expansion is the Main Complication of Chronic Type B Dissection

## Treatment with Stent Graft




35

## How to Follow?

1. Treatment
2. Surveillance
3. Patient Education

36


## Probability of Reintervention or Death After Type A Dissection Surgery



An KR, et al. *J Am Coll Cardiol* 2021;78:1863-71.

37


## Survival After Type A Dissection: False Lumen



Fattouch, *Ann Thorac Surg* 2009.  
224 pts acute DeBakey I dissection (early death 16%)  
189 survivors followed, 48 with Marfan syndrome

38


## Type B Large Entry Tear: Bad!? Entry Tear Size and Proximal Location



Cumulative survival free from sudden death and surgical/endovascular treatment by entry tear pattern (size and location). Prox indicates proximal.  
Copyright © American Heart Association, Inc. All rights reserved.  
Evangelista A, et al. *Circulation* 2012;125:3133-3141.

39

## Large Diameter: Bad !? Type B Survival Related to Total Aortic Diameter




Ray HM, et al. *J Vasc Surg* 2016;64:1560-68.

40

## Mean Reduction in Aortic Root Dilatation (mm/year) in Marfan Syndrome

- 9 RCTs with 1,271 participants showed that the combination of BB and ARB is the most effective for prevention of aortic root dilatation in MFS compared to control group [mean difference in mm/year (MD) -0.93; 95% CI (-1.35, -0.51)]
- When compared head to head, there is no difference between BB and ARB, but the combination of ARB-BB is significantly more effective (MD -0.31; 95% CI -0.55, -0.07)



Aaqib H. Malik et al. *J Am Coll Cardiol* 2019;73:582-582.

41


## Marfan Syndrome

Recommendations for Medical Therapy in Marfan Syndrome  
Referenced Studies that Support the Recommendations are Summarized in the [Online Data Supplement](#)

| COR | LOE  | Recommendations                                                                                                                                                                                   |
|-----|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1   | 4    | 1. In patients with Marfan Syndrome, treatment with either a beta blocker or an ARB, in maximally tolerated doses (unless contraindicated), is recommended to reduce the rate of aortic dilation. |
| 2a  | C-LD | 2. In patients with Marfan Syndrome, the use of both a beta blocker and an ARB, in maximally tolerated doses (unless contraindicated), is reasonable to reduce the rate of aortic dilation.       |

Same recommendation for LDS (Class 2a)

42



43

### Are There Commonly Used Drugs that Pose Aortic Risk?

|                                               |                                                                     |                                                                    |
|-----------------------------------------------|---------------------------------------------------------------------|--------------------------------------------------------------------|
| Calcium Channel Blockers                      | Ascending Aortic Dilation/Rupture in Marfan Mice                    | Signal of risk in Humans from GenTAC                               |
| Fluoroquinolones (Tendonitis, tendon rupture) | Aortic Aneurysm and Dissection in “Challenged” Mice (High Fat/↑ BP) | Epidemiologic Evidence of Aortic “Events” in Large Human Databases |


Lemaire, S.

44

| GenTAC Human Data        |                   |        |                |        |
|--------------------------|-------------------|--------|----------------|--------|
|                          | Aortic Dissection |        | Aortic Surgery |        |
|                          | Marfan            | Other  | Marfan         | Other  |
|                          | n=531             | n=1819 | n=531          | n=1819 |
| Odds in CCB              | 5.1%              | 0.57%  | 28.1%          | 10.70% |
| Odds in non-CCB          | 0.41%             | 0.12%  | 5.1%           | 4.4%   |
| Odds Ratio-CCB           | 12.5              | 4.7    | 5.5            | 2.4    |
| p-Value                  | 0.032             | NS     | <0.001         | <0.01  |
| Odds Ratio (BP)          | 12.7              | 5.6    | 5.4            | 2.2    |
| p-Value                  | 0.06              | NS     | <0.001         | 0.016  |
| Odds Ratio (Aortic Size) | 11.2              | 4.1    | 5.0            | 2.2    |
| p-Value                  | 0.08              | NS     | <0.01          | 0.017  |

Doyle JJ, et al. *eLife* 2015;4:e08648.

45



46

## Long Term Management of Aortic Dissection

- Medical management
  - Decrease dP/dT with beta blockers
  - Additional antihypertensives: ACE inhibitors, calcium channel blockers, etc
  - Goal is HR in 50's-60's, SBP 110-125
- Avoid heavy lifting or strain
  - Occupational responsibilities may be an issue
- Serial imaging studies to follow remaining aortic segments for aneurysm growth
  - Contrast-enhanced CT or MRI
  - Image abdominal aorta also if involved
  - 1, 3 and 6 months (consider 2 and 6 months)

47

## Pharmacological Treatment of Thoracic Aortic Disease


- ✓ Beta blocker/ ARB
  - ✓ Other antihypertensive medications to treat hypertension
  - ✓ Statins, at least when indicated, maybe broader use
- Endocarditis prophylaxis (AVR, aortic grafts, MVR, BAV)  
Contraception (in women using ARB's, or at higher risk with pregnancy)

Discussing exercise and limitations of exercise

Avoid Fluoroquinolone/Levaquin- I enter it as an "allergy" in EMR

**Influenza vaccine**

48



49

### Genetic Disorders: Thoracic Aortic Disease

| Genetic Syndrome              | Common Clinical Features                                                                                | Genetic Defect                           | Diagnostic Test                                                          |
|-------------------------------|---------------------------------------------------------------------------------------------------------|------------------------------------------|--------------------------------------------------------------------------|
| <b>Marfan Syndrome</b>        | Skeletal features<br>Ectopic lentle                                                                     | <i>FBN1</i> mutations*                   | Ghent diagnostic Criteria, DNA for sequencing                            |
| <b>Loeys-Dietz Syndrome</b>   | Bifid uvula or cleft palate<br>Arterial tortuosity<br>Hypertelorism                                     | <i>TGFBR2</i> or <i>TGFBR1</i> mutations | DNA for sequencing                                                       |
| <b>Ehlers-Danios Syndrome</b> | Thin, translucent skin<br>GI rupture<br>Rupture of gravid uterus<br>Rupture of medium to large arteries | <i>COL3A1</i> mutations                  | DNA for sequencing<br>Dermal fibroblasts for analysis of type 3 collagen |
| <b>Turner Syndrome</b>        | Short stature<br>Primary amenorhea<br>BAV<br>Aortic coarctation                                         | 45 X karyotype                           | Cells for karyotype analysis                                             |


\*The defective gene at a second locus for MFS is *TGFBR2* but the clinical phenotype as MFS is debated.

50


| Heritable Thoracic Aortic Disease Genes |                                                                                                                                                                                                                               |                                                                                 |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| ECM                                     | FBN-1 (fibrillin), COL3A1, MFAP5 (microfibril associated protein 5, BGN (Biglycan), LOX (lysyl oxidase), THSD4, ADAMS-like 6 protein                                                                                          | Related syndrome (when applicable):<br>Marfan syndrome (FBN-1)<br>vEDS (Col3A1) |
| TGF-β Signaling                         | TGFβR1 (TGF-b receptor type 1), TGFβR2 (TGF-b receptor type 2), SMAD3, SMAD4, TGFβ2,TGFβ3, latent TGF β-binding protein                                                                                                       | LDS type I-IV                                                                   |
| SMC                                     | ACTA2 (smooth muscle a-actin), MYH11 (SM myosin heavy chain), MYLK (myosin light chain kinase), PRKG1 (protein kinasecGMP-dependent kinase, MAT2A (methionine adenosyl transferase lia) FOXE3 (forkhead transcript factor E3) |                                                                                 |

M. Roman & J. De Baker. Hereditary TAD: How to save lives  
JTCVS 2022;163:39-45.


51




52




53



54



55




56

| Yield of Genetic Testing in Aortic Diseases |                                        |
|---------------------------------------------|----------------------------------------|
| Category                                    | Likelihood of Finding an Abnormal Gene |
| Syndromic Features                          | 90%                                    |
| Family History                              | 30%                                    |
| Dissection at Age ≤55                       | 10%                                    |


57

- | When to Perform Genetic Testing in Patients with Aortic Disease                                                                                                                                                                                                                                                                                                                     |  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| <ul style="list-style-type: none"><li>• Syndromic features with extra aortic manifestation suggestive for Marfan syndrome (MFS) and Loeys Dietz syndrome (LDS)</li><li>• Age &lt;60 years</li><li>• Family history of aortic, peripheral or intracranial aneurysm</li><li>• Family history of sudden cardiac death less than 50 years in first or second degree relatives</li></ul> |  |


58




59



60




61




62

# Searching for A Biomarker!




63


## Biomarkers “Targets” in Acute and Chronic Thoracic Aortic Disease




64




65




66




67



68




69



70

## 4D Flow – Estimate FL Pressurization




Burris N et al. *Eur J Cardiothorac Surg.* 11/2019 (In Press).

71

## False Lumen EF – Predicts Growth

- Medically managed type B dissection (n=18)
- FL Ejection Fraction independent-predictor of growth

| Aortic Growth Rate - Multivariate Model |         |      |              |         |
|-----------------------------------------|---------|------|--------------|---------|
| Variable                                | $\beta$ | SE   | 95% CI       | p-value |
| False Lumen EF                          | 0.15    | 0.04 | 0.06 – 0.24  | <0.01   |
| Baseline Aortic Diameter                | 0.37    | 0.14 | 0.07 – 0.68  | 0.02    |
| Follow-up Interval <sup>2</sup>         | -0.11   | 0.09 | -0.32 – 0.12 | 0.28    |
| Entry Tear Average Size                 | 0.21    | 0.18 | -0.18 – 0.60 | 0.26    |
| False Lumen Net Flow                    | -1.50   | 0.77 | -3.22 – 0.21 | 0.08    |
| False Lumen Peak Velocity               | 0.04    | 0.05 | -0.07 – 0.15 | 0.47    |
| Entry Tear Distance from LSC            | 0.07    | 0.02 | 0.01 – 0.13  | 0.02    |




Burris N et al. *Eur J Cardiothorac Surg.* 11/2019 (In Press).


72

# Aortic Length and Adverse Events

## Yearly Rates of AAEs



## Measuring Ascending Aortic Length



Wu J, et al. *J Am Coll Cardiol* 2019;74:1883-94.


73

# Dynamic Imaging: A Key Concept for Personalized Treatment and Follow-Up?



74


# Helicity Quantification



Clough RE, et al. *J Vasc Surg* 2012;55:914-23.

75


# Linear Flow - Good



Barker AJ, et al. *Circ Cardiovasc Imaging* 2012;5:457-466.

76


## Turbulent Flow – Bad!



Barker AJ, et al. *Circ Cardiovasc Imaging* 2012;5:457-466.

77

## Helicity and Outcomes



Clough RE, et al. *J Vasc Surg* 2012;55:914-23.

78

### Vascular Deformation Mapping (VDM)

- Image analysis technique for 3D aortic growth measurement.
  - **Input:** Thin-slice CT scans at 2 times
  - **Output:** Colorized 3D map of growth overlaid on aortic anatomy
- **Uses standard clinical CTA images**
  - No special scan procedures
- **Three-dimensional growth map**
  - Not subject to specific plane or direction
- **Sub-millimeter accuracy<sup>2</sup>**
  - Outperforms expert raters

**VDM Pipeline**

CT ANGIOGRAPHY

Baseline Follow-up

IMAGE PROCESSING

Aortic segmentation Deformable registration

VDM OUTPUT: 3D GROWTH MAP

Stable Ascending growth Descending growth

**Representative VDM Output**

2010→2018

Radial Growth Elongation

MFS patient with h/o ascending repair displaying rapid radial growth (left, 1.27 mm/y) and elongation (right) over 8-year period with subsequent development of acute TBAD in location of TA

1. Burris et al. *Radiology*. 2022.  
2. Bian et al. *Medical Physics*. 2022.

79

### Elevated 3D Growth in MFS w/ Type B Dissection

- **105 Ghent+ MFS patients at UM:** Mean CT surveillance interval of 8 years, 70% with prior root repair
- TBAD patients significantly more likely to be **female** and have **dural ectasia**.
  - No differences in age, BP, ACE/ARB & BB use, lens or mitral disease.
- Minimally dilated pre-dissection diameter (mean of 29 mm).

| VDM Analysis |                          | No TBAD<br>N=93  | TBAD<br>N=12     | p-value |
|--------------|--------------------------|------------------|------------------|---------|
| Radial       | Absolute growth (mm)     | 1.07 (0.6-2.9)   | 3.79 (2.09-7.68) | 0.001   |
|              | Growth rate (mm/y)       | 0.23 (0.13-0.35) | 0.63 (0.45-1.39) | <0.001  |
| Elongation   | Absolute elongation (mm) | 2.0 (-0.9, 8.0)  | 11.3 (5.3-19.3)  | 0.002   |
|              | Elongation rate (mm/y)   | 0.5 (-0.2, 1.4)  | 2.4 (1.3-4.5)    | <0.001  |

**Focal Growth in Representative Case of TBAD with Prior Ascending Repair**

Dissection location CT1 CT2 Follow-up CT


Growth rate of the proximal descending aorta = 0.51 mm/year

Pre-dissection interval Type B dissection

Radial growth rate threshold of **0.4 mm/y** shows 92% sensitivity, 81% specificity for TBAD


80

Representative case with TBAD




81

Representative case with TBAD



82



83

### Top Concerns of Aortic Dissection Survivors

| Question/Concern                                                                          | Percentage/Identifying |
|-------------------------------------------------------------------------------------------|------------------------|
| Does having the right educational resource for doctors improve health care for dissection | 54%                    |
| Does genetic testing improve health                                                       | 50%                    |
| What kind of exercise is safe & beneficial                                                | 47%                    |
| For subacute dissection, when is the right time for surgery                               | 47%                    |
| Does education of patients and families improve outcomes                                  | 44%                    |
| What meds are best?                                                                       | 32%                    |

Ref: Aortic Dissection Collaborative.

84

[www.gentacalliance.org](http://www.gentacalliance.org)

Contact

JOIN OUR NETWORK

About

Registries

Publications

Patient Resources

Research Initiatives

News & Events

Finding Solutions to Genetic Thoracic Aortic Diseases



85

On the Death of King George II in 1760:  
Aortic Dissection in Perspective

“On the 25<sup>th</sup> of October he [King George II] rose as usual at six, and drank his chocolate; for all his actions were invariable methodic. A quarter after seven he went into a little closet. His German valet de chambre in waiting heard a noise, and running in found the King dead on the floor. Nichols was directed to open and embalm the royal body. **What he found** (and meticulously described) **was the first clear account of the condition we now know** (after Laennec) **as aortic dissection (AD)**: “...the **pericardium was found distended with a quantity of coagulated blood, nearly a pint** ...; the whole heart was so compressed as to prevent any blood contained in the veins from being forced into the auricles; therefore the...



86

**Disease is very old, and nothing about it has changed.**

**It is we who change as we learn to recognize what was formerly imperceptible.**

*- Charcot*

87

Thanks to ALL the IRAD Centers and Investigators

|                                                          |                                               |                                      |                                  |                              |
|----------------------------------------------------------|-----------------------------------------------|--------------------------------------|----------------------------------|------------------------------|
| • Baylor College of Medicine                             | • Hôpital Bichat                              | • Minneapolis Heart Institute        | • Tufts Medical Center           | • University of Pittsburgh   |
| • Baylor Scott & White Heart & Vascular Hospital, Dallas | • Houston Methodist                           | • Monaldi Hospital                   | • University Hospital S. Orsola  | • University of Rostock      |
| • Baylor Scott & White Plano                             | • Hospital General Universitario Val d'Hebron | • Nanjing Medical University         | • University of Alabama          | • University of Salerno      |
| • Beth Israel Deaconess                                  | • Hospital Universitario "12 de Octubre"      | • Northwell Health                   | • University of Calgary          | • University of Texas Health |
| • Brigham & Women's Hospital                             | • IRCCS Policlinico San Donato                | • Radboud University                 | • University of Chicago          | • University of Tokyo        |
| • Dartmouth-Hitchcock                                    | • Massachusetts General                       | • Robert-Bosch Krankenhaus           | • University of Colorado         | • University of Vienna       |
| • Duke University                                        | • Mayo Clinic                                 | • St. Michael's Hospital             | • University of Florida          | • University of Virginia     |
| • East Carolina University                               | • MedNet the MedCity                          | • St. Thomas Health                  | • University of Maryland         | • University of Washington   |
| • Emory University                                       | • Medical University of Graz                  | • The Technische Universität München | • University of Medicine Arizona | • University of Wisconsin    |
| • Hartford Healthcare                                    | • Memorial Care                               | • Toronto General Hospital           | • University of Michigan         | • Vanderbilt University      |
| • Hadassah University Hospital                           |                                               | • Tromsø University Hospital         | • University of Minnesota        | • Washington University      |
|                                                          |                                               |                                      | • University of Pennsylvania     |                              |

88

# University of Michigan Collaborators

**IRAD Core**

Jim Froehlich  
Eva Kline-Rogers  
Chih-Wen Pai  
Patsy Bruenger  
Tina Alexandris-Souphis  
Elise Woznicki

**UM Aortic Program**

G. Michael Deeb  
Jon Eliason  
David Williams  
Himanshu Patel

**UM Aortic Program**

Santhi Ganesh  
Kristen Willer  
Stan Chetcuti  
Bill Armstrong  
Mike Shea  
Troy LaBounty  
Bo Yang  
Nicole Bhav  
Shinichi Fukuhara  
Marion Hofmann Bowman  
Gorav Ailawadi  
Barbara Hamilton  
Nicholas Burris

89

“There is no disease more  
conducive to clinical humility  
than aneurysm of the aorta”

- Sir William Osler

90

# Acknowledgements

## Mentorship

- Dr. Larry Cohen – Joy of Cardiology & Professionalism
- Dr. Roman DeSanctis – My “Medical” Father
- Dr. George Thibault – Outcomes & Guidelines
- Dr. Valentin Fuster – Think Global – Anything possible!

## Support

- Mr. & Mrs. Walter Eagle – Value of hard work, honesty & family
- Mr. Donald S. Hopkins – Invested in my career
- Mrs. Darlene Farrell Eagle – Lifelong companion
- Mr. Taylor Eagle – My greatest legacy?
- Countless others: Colleagues, students, patients, and family members

*Faith, family, friends, colleagues...These are the “things” that matter...*